ORPHA:2912
Poliomyelitis
Publications
104,067
Trials
247
Interventional, condition-specific
Researchers
1,267
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare viral infection caused by any of three serotypes of wild human poliovirus (types 1, 2 and 3), which are part of the family of enteroviruses; and three serotypes of Sabin vaccine-derived polioviruses (types 1, 2 and 3) that have accumulated genetic changes and regained the ability to cause polio paralysis. wild type 2 and type 3 polioviruses have been certified eradicated, wild type 1 poliovirus continues to circulate in Pakistan and Afghanistan, and vaccine-derived polio viruses mainly circulate in sub-Saharan Africa.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017373
- MeSH:D011051
- UMLS:C0032371
- NCIT:C35550
Additional Mondo synonyms (4)
Polia · acute poliomyelitis · polio · poliomyelitis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
104,067 matched papers (38,538 in last 10 years) Source
- Phenotype characterisedPresent
73 HPO annotations (e.g. Paralysis; Sleep disturbance; Fasciculations) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
247 matched on ClinicalTrials.gov (16 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
73
Associated phenotypes · MONDO:0017373
- Paralysis
- Sleep disturbance
- Fasciculations
- Skeletal muscle atrophy
- Muscle spasm
Showing 5 of 73 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
6
Drugs / clinical candidates · MONDO_0017373
- BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ·approval
- BORDETELLA PERTUSSIS PERTACTIN AUTOTRANSPORTER·approval
- DIPHTHERIA TOXOID·approval
- HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN·approval
- NOREPINEPHRINE BITARTRATE·approval
- TETANUS TOXOID·approval
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
104,067
104,067 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
104,067 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
38,538 in the last 10 years · low confidence
Phrase hits: 104,067 · MeSH hits: 0
Who's working on it?
1,267
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Zhang Y7 papers · 2026
Expanded Program on Immunization, Chongqing Municipal Center for Disease Control and Prevention, Chongqing, China.
Papers in Europe PMC - 02Liu Y6 papers · 2026
Expanded Program on Immunization, Chongqing Municipal Center for Disease Control and Prevention, Chongqing, China.
Papers in Europe PMC - 03Bandyopadhyay AS4 papers · 2026
Bill and Melinda Gates Foundation, Polio Team, Seattle, Washington, USA.
Papers in Europe PMC - 04Blake IM4 papers · 2026
School of Public Health, Medical Research Council Centre for Global Infectious Disease Analysis, Imperial College London, London, United Kingdom.
Papers in Europe PMC - 05Grassly NC4 papers · 2026
School of Public Health, Medical Research Council Centre for Global Infectious Disease Analysis, Imperial College London, London, United Kingdom.
Papers in Europe PMC - 06Ivin YY4 papers · 2025
Institute of Biomedical Chemistry, 10 Pogodinskaya str., 119121 Moscow, Russia.
Papers in Europe PMC - 07Kozlovskaya LI4 papers · 2025
Federal State Autonomous Scientific Institution "Chumakov Federal Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences" (Institute of Poliomyelitis) (FSASI "Chumakov FSC R&D IBP RAS"), 108819 Moscow, Russia.
Papers in Europe PMC - 08Li X4 papers · 2026
Department of Respiratory and Critical Care Medicine, Binzhou Medical University Hospital, Binzhou, Shandong, China.
Papers in Europe PMC - 09Li Y4 papers · 2026
Daiyue District Center for Disease Control and Prevention, Taian 271000, China.
Papers in Europe PMC - 10Maccari G4 papers · 2025
Data Science for Health Lab, Fondazione Toscana Life Sciences, 53100 Siena, Italy.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
247
interventional trials for this specific condition
247 interventional trials matched this specific condition name; 16 currently recruiting in our sample.
Data as of 11 September 2026
247 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 99.5th percentile).
low confidence · 99.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
247 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07010822·NOT YET RECRUITING·A Study to Evaluate the Mucosal Intestinal Immunity to Poliovirus Type-2 of nOPV2 at Birth Dose in Healthy IPV Vaccinated Infants
Not reviewed·Conditions: Poliomyelitis·Matched via name phrase
- NCT06895486·RECRUITING·Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation
Not reviewed·Conditions: Poliomyelitis·Matched via name phrase
- NCT05644184·RECRUITING·Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh
Not reviewed·Conditions: Poliomyelitis·Matched via name phrase
- NCT06577298·RECRUITING·A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers
Not reviewed·Conditions: Poliomyelitis·Matched via name phrase
- NCT06748612·NOT YET RECRUITING·Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)
Not reviewed·Conditions: Polio·Matched via name phrase
- NCT05654467·RECRUITING·Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama
Not reviewed·Conditions: Poliomyelitis·Matched via name phrase
- NCT07688369·NOT YET RECRUITING·Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults
Not reviewed·Conditions: Polio Immunity·Matched via name phrase
- NCT06460545·NOT YET RECRUITING·Phase IV Study of Concomitant Administration of the sIPV and HepA
Not reviewed·Conditions: Polio · Hepatitis A·Matched via name phrase
- NCT06920069·NOT YET RECRUITING·Study of Concomitant Administration of the sIPV and DTaP or MMR
Not reviewed·Conditions: Polio · Diphteria, Tetanus and Pertussis · MMR Vaccine·Matched via name phrase
- NCT07457060·RECRUITING·Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine
Not reviewed·Conditions: Poliomyelitis·Matched via name phrase
- NCT06137664·RECRUITING·Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines
Not reviewed·Conditions: Poliomyelitis·Matched via name phrase
- NCT06605755·RECRUITING·Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants
Not reviewed·Conditions: Pertussis · Diphtheria · Tetanus · Haemophilus Influenzae Type B Infection·Matched via name phrase
- NCT06618196·NOT YET RECRUITING·Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age
Not reviewed·Conditions: Diphtheria · Tetanus · Pertussis · Hepatitis B·Matched via name phrase
- NCT07354269·RECRUITING·Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations
Not reviewed·Conditions: Poliomyelitis·Matched via name phrase
- NCT05644522·RECRUITING·Nomad P-KAFO Study
Not reviewed·Conditions: Cerebrovascular Accident · Post-polio Syndrome · Spinal Cord Injuries · Multiple Sclerosis·Matched via name phrase
Observational and natural-history studies
22 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07338851·NOT YET RECRUITING·the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
Not reviewed·Conditions: Polio · Measles · Rubella · Mumps·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 22 · after dedupe 22 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 22 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (22)
- isrctn·ISRCTN55932023·No longer recruiting·Study of a virtual reality intervention for pain and anxiety control in pediatric vaccination
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN93905494·No longer recruiting·A trial to assess the practicality of delivering fractional doses of an inactivated poliovirus vaccine in a community-based campaign in under 5 year-olds in a rural setting in The Gambia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN20019630·No longer recruiting·UNITING: UNderstanding uptake of Immunisations in TravellIng aNd Gypsy communities
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN64117538·No longer recruiting·Booster study: long term cellular memory immunity against Bordetella pertussis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN64725429·No longer recruiting·Comparative evaluation of immunogenicity and reactogenicity of monovalent type 2 and 3 oral poliovirus vaccines (mOPV 2 and mOPV3) versus trivalent oral poliovirus vaccine (tOPV), and bivalent oral poliovirus vaccine (bOPV) versus monovalent types 1 and 3 oral poliovirus vaccines, respectively: a randomised double-blind trial
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN90744784·No longer recruiting·Evaluation of humoral immune response induced by a supplemental dose of inactivated poliovirus vaccine (IPV) administered intradermally or intramuscularly versus a dose of monovalent type 1 oral poliovirus vaccine
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN82484612·No longer recruiting·A phase II, double-blind, randomised, controlled, dose ranging study to evaluate the safety, immunogenicity, dose response and schedule response of a meningococcal A conjugate vaccine administered concomitantly with local expanded program on immunisation (EPI) vaccines in healthy infants
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18107202·No longer recruiting·Comparative evaluation of Immunogenicity of monovalent type 1 Oral Poliovirus Vaccine (mOPV1) and monovalent type 3 Oral Poliovirus Vaccine (mOPV3) versus trivalent Oral Poliovirus Vaccine (tOPV): a randomised double-blind controlled trial in South Africa
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN00378146·No longer recruiting·Cost-utility and efficacy of a home-based exercise program in poliomyelitis survivors
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN54186735·No longer recruiting·A phase-IV randomised, double blind comparative evaluation of immunogenicity of Monovalent Type 1 Oral Poliomyelitis Vaccine (mOPV1) versus trivalent OPV (tOPV): four-armed study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN19673867·No longer recruiting·Immune response of fractional doses of Inactivated Poliovirus Vaccine (IPV) administered intradermally in Cuba
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17418767·No longer recruiting·Immune response of fractional doses of Inactivated Poliovirus Vaccine (IPV) administered intradermally in the Sultanate of Oman
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN97785537·No longer recruiting·Immunogenicity and adjuvant effect of the whole cell Pertussis component of the Dutch combined Diphtheria, Tetanus, Pertussis, Poliomyelitis - Haemophilus influenzae type b vaccine in infants compared to the old whole cell P vaccine and a new acellular P vaccine component
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN45122933·No longer recruiting·German trial of Acyclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11877362·No longer recruiting·A phase II, double-blind, randomised, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 106.5 CCID50) administered to human immunodeficiency virus (HIV) infected infants at 6, 10 and 14 weeks of age in South Africa
skipped — LLM skipped (--skip-llm)
- ctis·2025-524635-39-00·Authorised·An Open Label, Single Arm, Phase I/II Clinical Study of Autologous CD4+ T-Cells Edited Ex-Vivo at the CD40LG Locus by CRISPR/Cas9 and IDLV-based vector in Patients with X-linked Hyper IgM Syndrome Type 1 (HIGM1)
skipped — LLM skipped (--skip-llm)
- ctis·2025-521752-26-00·Authorised, ongoing·A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
skipped — LLM skipped (--skip-llm)
- ctis·2025-522406-20-00·Authorised, recruiting·A Phase 1b/2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate A) the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of IM-101 in Adult Participants with Generalized Myasthenia Gravis, and B) the Efficacy and Safety of Treatment of IM-101 in Adult Participants with Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
skipped — LLM skipped (--skip-llm)
- ctis·2023-510465-10-00·Expired·A parallel-group prevention, Phase II, partially blinded, multi-stage study to investigate the immunogenicity and safety of Pentavalent Meningococcal ABCYW Vaccine formulations compared with licensed meningococcal vaccines when administered alone in healthy children (2 to 9 years of age) or concomitantly with routine pediatric vaccines in toddlers (12 to 15 months of age) and infants (2 months of age).
skipped — LLM skipped (--skip-llm)
- ctis·2024-517893-73-00·Cancelled·Maternal determinants of infant immunity to pertussis (MADI-02)
skipped — LLM skipped (--skip-llm)
- ctis·2023-508416-35-00·Cancelled·A phase 4, randomised vaccination study in healthy adults to investigate the effects of acellular pertussis vaccine on colonisation with Bordetella pertussis using controlled human infection (KIM-study)
skipped — LLM skipped (--skip-llm)
- ctis·2023-506449-40-00·Cancelled·A Phase II, Randomized, Partially Blinded Study to Assess the Safety, Tolerability and Immunogenicity of Meningococcal Combined ABCWY Vaccine when Administered to Healthy Infants
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Poliomyelitis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Poliomyelitis" OR "Polia" OR "acute poliomyelitis" OR "polio"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Poliomyelitis" OR "Polia" OR "acute poliomyelitis" OR "polio"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 247 interventional · 22 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (104067) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-26T21:39:42.628Z
